{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:11:26Z","timestamp":1790734286365,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijantimicag.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T18:30:45Z","timestamp":1556303445000},"page":"197-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model"],"prefix":"10.1016","volume":"54","author":[{"given":"Kevin A.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda T.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8400","authenticated-orcid":false,"given":"Eric","family":"Wenzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0001","series-title":"Antibiotic resistance threats in the United States","year":"2013"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0002","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: a pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0003","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/cid\/ciy064","article-title":"A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis","volume":"67","author":"Beganovic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0005","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0006","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/48.2.283","article-title":"In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci","volume":"48","author":"Noviello","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0008","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.44.11.3017-3021.2000","article-title":"Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis","volume":"44","author":"Lefort","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/1744-7917.12325","article-title":"Immunity of the greater wax moth Galleria mellonella","volume":"24","author":"Wojda","year":"2017","journal-title":"Insect Sci"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.micinf.2007.02.016","article-title":"Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain","volume":"9","author":"Aperis","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0011","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1128\/IAI.73.7.3842-3850.2005","article-title":"Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis","volume":"73","author":"Mylonakis","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0012","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1128\/AAC.01533-08","article-title":"Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics","volume":"53","author":"Peleg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0013","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/21505594.2015.1135289","article-title":"Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing","volume":"7","author":"Tsai","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0014","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1371\/journal.ppat.0030101","article-title":"Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi","volume":"3","author":"Mylonakis","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.femsre.2003.09.002","article-title":"Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens","volume":"28","author":"Kavanagh","year":"2004","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-394805-2.00002-6","article-title":"Utility of greater wax moth larva (Galleria mellonella) for evaluating the toxicity and efficacy of new antimicrobial agents","volume":"78","author":"Desbois","year":"2012","journal-title":"Adv Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkz010","article-title":"In vitro activity of oritavancin alone or in combination against vancomycin susceptible and resistant enterococci","author":"Wu","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0018","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02001-17","article-title":"Evaluation of non-tissue culture- versus tissue culture-treated microplates for oritavancin susceptibility testing","volume":"56","author":"Yan","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","article-title":"In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014","volume":"46","author":"Biedenbach","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0021","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.02790-13","volume":"58","author":"Luther","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0022","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijantimicag.2016.12.006","article-title":"Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model","volume":"49","author":"Skinner","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.04.010_bib0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkx419","article-title":"In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae","volume":"73","author":"Nath","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:14Z","timestamp":1760376794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0924857919301049"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}